BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31502717)

  • 1. Analytically validated protein biomarkers of chronic pancreatitis and pancreatic cancer for potential clinical diagnosis with mass spectrometry.
    Chou CY; Chang CT; Chen CJ
    Rapid Commun Mass Spectrom; 2020 Apr; 34 Suppl 1():e8580. PubMed ID: 31502717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
    Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis.
    Saraswat M; Joenväärä S; Seppänen H; Mustonen H; Haglund C; Renkonen R
    Cancer Med; 2017 Jul; 6(7):1738-1751. PubMed ID: 28573829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying proteomic-based biomarker tools for the accurate diagnosis of pancreatic cancer.
    Kojima K; Asmellash S; Klug CA; Grizzle WE; Mobley JA; Christein JD
    J Gastrointest Surg; 2008 Oct; 12(10):1683-90. PubMed ID: 18709425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted mass spectrometry approaches for protein biomarker verification.
    Meng Z; Veenstra TD
    J Proteomics; 2011 Nov; 74(12):2650-9. PubMed ID: 21540133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
    Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
    Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SELDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of a boosting decision tree model for diagnosis of pancreatic cancer.
    Qian JY; Mou SH; Liu CB
    Asian Pac J Cancer Prev; 2012; 13(5):1911-5. PubMed ID: 22901146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
    Lee MJ; Na K; Jeong SK; Lim JS; Kim SA; Lee MJ; Song SY; Kim H; Hancock WS; Paik YK
    J Proteome Res; 2014 Nov; 13(11):4878-88. PubMed ID: 25057901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach.
    Park J; Lee E; Park KJ; Park HD; Kim JW; Woo HI; Lee KH; Lee KT; Lee JK; Park JO; Park YS; Heo JS; Choi SH; Choi DW; Jang KT; Lee SY
    Oncotarget; 2017 Jun; 8(26):42761-42771. PubMed ID: 28514751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling.
    Pan S; Chen R; Crispin DA; May D; Stevens T; McIntosh MW; Bronner MP; Ziogas A; Anton-Culver H; Brentnall TA
    J Proteome Res; 2011 May; 10(5):2359-76. PubMed ID: 21443201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of pancreatic juice proteins as biomarkers of pancreatic cancer.
    Gao J; Zhu F; Lv S; Li Z; Ling Z; Gong Y; Jie C; Ma L
    Oncol Rep; 2010 Jun; 23(6):1683-92. PubMed ID: 20428826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-translational modifications of pancreatic fluid proteins collected via the endoscopic pancreatic function test (ePFT).
    Paulo JA; Kadiyala V; Brizard S; Banks PA; Steen H; Conwell DL
    J Proteomics; 2013 Oct; 92():216-27. PubMed ID: 23500127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue.
    Zhou Q; Andersson R; Hu D; Bauden M; Kristl T; Sasor A; Pawłowski K; Pla I; Hilmersson KS; Zhou M; Lu F; Marko-Varga G; Ansari D
    EBioMedicine; 2019 May; 43():282-294. PubMed ID: 30982764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis.
    Chang MC; Chang YT; Su TC; Yang WS; Chen CL; Tien YW; Liang PC; Wei SC; Wong JM
    Pancreas; 2007 Jul; 35(1):16-21. PubMed ID: 17575540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer.
    Chen R; Brentnall TA; Pan S; Cooke K; Moyes KW; Lane Z; Crispin DA; Goodlett DR; Aebersold R; Bronner MP
    Mol Cell Proteomics; 2007 Aug; 6(8):1331-42. PubMed ID: 17496331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.
    Kuwatani M; Kawakami H; Kubota Y; Kawakubo K; Ito YM; Togo S; Ikeda T; Kusama K; Kobayashi Y; Murata T; Sakamoto N
    Pancreatology; 2019 Jun; 19(4):569-577. PubMed ID: 31031206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary Peptide Analysis Differentiates Pancreatic Cancer From Chronic Pancreatitis.
    Schönemeier B; Metzger J; Klein J; Husi H; Bremer B; Armbrecht N; Dakna M; Schanstra JP; Rosendahl J; Wiegand J; Jäger M; Mullen W; Breuil B; Plentz RR; Lichtinghagen R; Brand K; Kühnel F; Mischak H; Manns MP; Lankisch TO
    Pancreas; 2016 Aug; 45(7):1018-26. PubMed ID: 26784907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.